According to a new report, published by KBV research, The Global Mycoplasma Testing Market size is expected to reach $1.9 billion by 2030, rising at a market growth of 11.5% CAGR during the forecast period.
The Kits & Reagents segment generated the highest revenue in the Global Mycoplasma Testing Market by Product & Service in 2022; thereby, achieving a market value of $933.4 million by 2030. Mycoplasma testing kits typically come with ready-to-use reagents and detailed protocols, simplifying the testing process. This ease of use is especially valuable for researchers and laboratory technicians, enabling them to perform mycoplasma testing without extensive molecular biology or microbiology expertise. Kits & reagents are designed and manufactured under controlled conditions, minimizing the risk of contamination. Using pre-packaged reagents reduces the chances of errors in the preparation of testing solutions, enhancing the overall reliability of mycoplasma testing results.
The PCR segment is registering a CAGR of 10.9 % during the forecast period. PCR provides high specificity, allowing the selective amplification of mycoplasma DNA sequences. This specificity ensures that the identified DNA is from mycoplasma contamination and no other microorganisms in the sample, reducing the possibility of false-positive results. PCR enables rapid detection of mycoplasma contamination. Traditional mycoplasma detection methods, such as culture-based techniques, can take several weeks, while PCR can provide results within a few hours. This speed is particularly advantageous in time-sensitive applications, such as biopharmaceutical production.
The Cell Line Testing segment led the Global Mycoplasma Testing Market by Application in 2022; thereby, achieving a market value of $934.5 million by 2030. The biopharmaceutical industry relies heavily on cell lines to produce therapeutic proteins, monoclonal antibodies, and vaccines. As the biopharmaceutical continues to grow, the need for mycoplasma testing in cell lines becomes more pronounced to ensure the safety and quality of biopharmaceutical products. The development and commercialization of cell-based therapies, including gene and cell therapies, have witnessed significant growth. These therapies often involve cultured cells, making mycoplasma testing essential to prevent contamination and ensure the safety of these advanced therapeutic products.
The Pharmaceutical & Biotechnology Companies segment is growing at a CAGR of 10.9 % during the forecast period. Mycoplasma testing is crucial in producing biopharmaceuticals, including monoclonal antibodies, recombinant proteins, and other therapeutic proteins. Ensuring that cell cultures used in production are free from mycoplasma contamination is vital for the quality and safety of the final products. Biotechnology companies are engaged in cell line development to produce various biologics. Mycoplasma testing is used to monitor and verify the absence of mycoplasma contamination during the development of cell lines, preventing issues downstream in the production process.
Full Report: https://www.kbvresearch.com/mycoplasma-testing-market/
The North America region dominated the Global Mycoplasma Testing Market by Region in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $756.2 million by 2030. The Europe region is anticipated to grow at a CAGR of 11.1% during (2023 - 2030). Additionally, The Asia Pacific region would witness a CAGR of 12.4% during (2023 - 2030).
By Product & Service
By Technology
By Application
By End User
Unique Offerings 
